Why Sarepta Therapeutics (SRPT) Is Up 12.7% After FDA Accepts sNDAs Backed By ESSENCE Data

Simply Wall St.07-08

In late June 2026, Sarepta Therapeutics reported that the FDA accepted for filing supplemental New Drug Applications to convert accelerated approvals for its Duchenne muscular dystrophy therapies ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649907931?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-08 00:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649907931","market":"us","top_or_hot":-1,"title":"Why Sarepta Therapeutics (SRPT) Is Up 12.7% After FDA Accepts sNDAs Backed By ESSENCE Data","media":"Simply Wall St.","content":"<div>\n<p>In late June 2026, Sarepta Therapeutics reported that the FDA accepted for filing supplemental New Drug Applications to convert accelerated approvals for its Duchenne muscular dystrophy therapies ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/why-sarepta-therapeutics-srpt-is-up-127-after-fda-accepts-sn\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Sarepta Therapeutics (SRPT) Is Up 12.7% After FDA Accepts sNDAs Backed By ESSENCE Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Sarepta Therapeutics (SRPT) Is Up 12.7% After FDA Accepts sNDAs Backed By ESSENCE Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-08 00:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/why-sarepta-therapeutics-srpt-is-up-127-after-fda-accepts-sn><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late June 2026, Sarepta Therapeutics reported that the FDA accepted for filing supplemental New Drug Applications to convert accelerated approvals for its Duchenne muscular dystrophy therapies ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/why-sarepta-therapeutics-srpt-is-up-127-after-fda-accepts-sn\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SRPU","symbol_name":"2倍做多SRPT ETF-Tradr","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/why-sarepta-therapeutics-srpt-is-up-127-after-fda-accepts-sn","article_id":"2649907931","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/why-sarepta-therapeutics-srpt-is-up-127-after-fda-accepts-sn","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2649907931","pubTimestamp":1783441923,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late June 2026, Sarepta Therapeutics reported that the FDA accepted for filing supplemental New Drug Applications to convert accelerated approvals for its Duchenne muscular dystrophy therapies AMONDYS 45 and VYONDYS 53 into traditional approvals, supported by Phase 3 ESSENCE data and extensive real‑world evidence.\nAlthough the ESSENCE trial did not meet its primary endpoint, treatment-favoring trends, long-term safety data and real-world functional benefits could materially influence how...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"SRPU":"2倍做多SRPT ETF-Tradr","BK4588":"碎股","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4585":"ETF&股票定投概念","SRPT":"Sarepta Therapeutics","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4139":"生物科技","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LABU":"三倍做多标普生物-Direxion","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC"},"translate_title":"为什么FDA接受由ESSENCE数据支持的SNDA后Sarepta Therapeutics(SRPT)上涨12.7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRPU":0.6,"SRPT":1.5,"LABU":1.5},"content_text":"In late June 2026, Sarepta Therapeutics reported that the FDA accepted for filing supplemental New Drug Applications to convert accelerated approvals for its Duchenne muscular dystrophy therapies AMONDYS 45 and VYONDYS 53 into traditional approvals, supported by Phase 3 ESSENCE data and extensive real‑world evidence. Although the ESSENCE trial did not meet its primary endpoint, treatment-favoring trends, long-term safety data and real-world functional benefits could materially influence how investors assess the durability and quality of Sarepta’s DMD franchise. We’ll now examine how the FDA’s acceptance of these sNDAs, backed by ESSENCE and real-world evidence, could reshape Sarepta’s investment narrative. The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it. Find the list for free.AdvertisementSarepta Therapeutics Investment Narrative RecapTo own Sarepta today, you have to believe its Duchenne muscular dystrophy portfolio can sustain meaningful, durable demand despite safety concerns around ELEVIDYS and near term revenue volatility. The FDA’s acceptance of sNDAs for AMONDYS 45 and VYONDYS 53 does not change the fact that ELEVIDYS remains the key catalyst and the central risk, but it does slightly strengthen the foundation of Sarepta’s broader DMD franchise. The recent reshuffling of Sarepta’s index memberships, with the stock leaving the Russell 1000 and entering the Russell 2000 and related benchmarks, is the most relevant additional development. While this does not alter the clinical or regulatory outlook, it may influence who holds the shares around key catalysts such as the ELEVIDYS safety updates and the 2027 PDUFA date for AMONDYS 45 and VYONDYS 53. But against this stronger DMD backbone, the unresolved ELEVIDYS safety questions are something investors should be aware of as they consider... Read the full narrative on Sarepta Therapeutics (it's free!)Sarepta Therapeutics' narrative projects $1.4 billion revenue and $87.3 million earnings by 2029. This implies revenues decline by 13.3% per year and an earnings increase of about $800 million from -$713.4 million today.Uncover how Sarepta Therapeutics' forecasts yield a $21.65 fair value, a 13% upside to its current price.Exploring Other PerspectivesSRPT 1-Year Stock Price Chart Before this update, the most optimistic analysts were banking on revenue near US$1.6 billion and earnings around US$232.7 million by 2029, assuming ELEVIDYS and new programs scale smoothly, which is far more upbeat than the caution implied by current ELEVIDYS safety and access risks, so you should recognize how far apart these views can be and consider how this new FDA development might pull expectations in either direction.Explore 5 other fair value estimates on Sarepta Therapeutics - why the stock might be worth less than half the current price!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Sarepta Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.Our free Sarepta Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sarepta Therapeutics' overall financial health at a glance.Want Some Alternatives?The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Find 41 companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649907931","isCrawlerRequest":true}